In An Organic Compound Patents (Class 424/1.65)
-
Publication number: 20150118156Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: ApplicationFiled: December 23, 2014Publication date: April 30, 2015Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
-
Patent number: 9017644Abstract: The present invention relates to dendrimer compositions configured for treating inflammatory disorders and autoimmune disorders, and related methods of synthesis. Specifically, the present invention relates to methods for treating rheumatoid arthritis with PAMAM dendrimers having functional ligands configured for treating rheumatoid arthritis (e.g., therapeutic agents, pro-drugs, targeting agents, trigger agents, imaging agents) (e.g., methotrexate).Type: GrantFiled: November 9, 2009Date of Patent: April 28, 2015Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., Larry A. Sternson, David Repp, Deborah Ladenheim
-
Publication number: 20150110715Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.Type: ApplicationFiled: July 18, 2014Publication date: April 23, 2015Applicants: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
-
Publication number: 20150110713Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20150110716Abstract: A method of evaluating a subject suspected of harboring a prostrate tumor includes administering to the subject an effective amount of a gamma-emitting transition metal complex conjugated to a targeting moiety that selectively binds to prostate-specific membrane antigen (PSMA), including PSMA expressed on the surface of a prostate tumor; subjecting the subject to a nuclear medicine tomographic imaging technique to obtain one or more images of at least a portion of prostate tissue that comprises tumor lesions; assessing a level of uptake of said gamma-emitting transition metal complex conjugated to a targeting moiety by said at least a portion of prostate tissue compared to a level of uptake by control tissue; and determining if a ratio of the level of uptake by said at least a portion of prostate tissue compared the level of uptake by control tissue is at or above a predetermined threshold.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Applicant: Molecular Insight Pharmaceuticals, Inc.Inventor: Thomas ARMOR
-
Patent number: 9011816Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.Type: GrantFiled: March 25, 2011Date of Patent: April 21, 2015Assignee: Case Western Reserve UniversityInventors: Zheng-Rong Lu, Xueming Wu
-
Publication number: 20150104387Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: ApplicationFiled: April 2, 2014Publication date: April 16, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
-
Patent number: 9005577Abstract: The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: GrantFiled: April 30, 2009Date of Patent: April 14, 2015Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Umesh B. Gangadharmath, Gang Chen, Vani P. Mocharla, Dhanalakshmi Kasi, Peter J. H. Scott, Qianwa Liang
-
Patent number: 9005578Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.Type: GrantFiled: May 28, 2013Date of Patent: April 14, 2015Assignees: Fluoropharma, Inc., The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
-
Patent number: 9005575Abstract: The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma.Type: GrantFiled: May 28, 2010Date of Patent: April 14, 2015Assignee: STC.UNMInventors: Yubin Miao, Jianquan Yang
-
Publication number: 20150098903Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.Type: ApplicationFiled: December 15, 2014Publication date: April 9, 2015Inventors: David R. Elmaleh, Timothy M. Shoup, Hongning Fu
-
Publication number: 20150086479Abstract: The invention provides a process for forming a layered nanoparticle, comprising providing a suspension comprising a core particle in a first liquid, adding a second liquid to the suspension, and adding a reagent, or a precursor for the reagent, to the suspension. The second liquid is immiscible with the first liquid. If the reagent is added to the suspension, the reagent reacts to form a layer on the core particle to form the layered nanoparticle. If a precursor for the reagent is added to the suspension, the precursor is converted to the reagent, and the reagent reacts to form a layer on the core particle to form the layered nanoparticle.Type: ApplicationFiled: September 4, 2014Publication date: March 26, 2015Inventors: Christophe Jean Alexandre BARBE, Linggen KONG
-
Publication number: 20150086480Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: ApplicationFiled: September 26, 2014Publication date: March 26, 2015Inventors: Emily Catherine D'Amato, Mark Gurney, Xuesheng Mo, Richard A. Nugent
-
Patent number: 8986650Abstract: The present invention concerns a Ga68 complex of formula FOLATE-(LINKER)i-NOTA-Ga68 in which: 1) FOLATE is a folate compound or a derivative thereof capable of targeting a folate receptor, 2) NOTA is a chelate capable of complexing Ga68 having a NOTA scaffold or derivatives thereof 3) LINKER is a chemical group linking FOLATE and NOTA 4) i is an integer chosen between 0 and 1 wherein NOTA is complexing Ga68.Type: GrantFiled: August 8, 2011Date of Patent: March 24, 2015Assignee: GuerbetInventors: Marc Port, Claire Corot, Thierry Gautheret
-
Publication number: 20150078997Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.Type: ApplicationFiled: September 22, 2014Publication date: March 19, 2015Applicant: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
-
Publication number: 20150078998Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: Pharmaceutical compositions may include a complex of a radionuclide and a compound of Formula I or Formula II.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Applicant: MOLECULAR INSIGHT PHARMACEUTICALSInventors: John W. BABICH, Craig ZIMMERMAN, John L. JOYAL, Genliang LU
-
Patent number: 8980185Abstract: A microreactor for preparing a radiolabeled complex or a biomolecule conjugate comprises a microchannel for fluid flow, where the microchannel comprises a mixing portion comprising one or more passive mixing elements, and a reservoir for incubating a mixed fluid. The reservoir is in fluid communication with the microchannel and is disposed downstream of the mixing portion. A method of preparing a radiolabeled complex includes flowing a radiometal solution comprising a metallic radionuclide through a downstream mixing portion of a microchannel, where the downstream mixing portion includes one or more passive mixing elements, and flowing a ligand solution comprising a bifunctional chelator through the downstream mixing portion. The ligand solution and the radiometal solution are passively mixed while in the downstream mixing portion to initiate a chelation reaction between the metallic radionuclide and the bifunctional chelator. The chelation reaction is completed to form a radiolabeled complex.Type: GrantFiled: August 25, 2011Date of Patent: March 17, 2015Assignees: The Board of Trustees of the University of Illinois, Washington UniversityInventors: David E. Reichert, Paul J. A. Kenis, Tobias D. Wheeler, Amit V. Desai, Dexing Zeng, Birce C. Önal
-
Publication number: 20150064110Abstract: The present invention relates to a method for preparing beads comprising imaging agent. The present invention further provides beads highly useful for medical imaging.Type: ApplicationFiled: February 22, 2013Publication date: March 5, 2015Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Diderot - Paris 7, Univ Paris XIII Paris-Nord VilletaneuseInventors: Sidi Mohammed Derkaoui, Catherine Le Visage, Thomas Bonnard, Didier LeTourneur, Jean-Michel Serfaty
-
Publication number: 20150064109Abstract: The invention provides a novel quantitative method for differentiating and identification of changes in tissue by enhancing differences in blood flow prior to administering a radiopharmaceutical, which differentially accumulates in tissue based upon differences in blood flow and metabolic activity. In one embodiment the enhancing agent is 0.852 mg per kilogram body weight dipyridamole and the radiopharmaceutical is Technetium-99m hexakis 2-methoxyisobutylisonitrile (sestamibi) and the tissue differentiation is calcification, normal, inflammatory, precancerous and cancerous breast tissue. The present invention allows differentiation between regions of calcification, nonliving or metabolically inactive tissue, normal tissue, pre-cancerous and cancerous tissue. The present invention allows for quantification of changes in tissue to determine the effect of treatment upon tissue.Type: ApplicationFiled: August 29, 2013Publication date: March 5, 2015Inventor: Richard Max Fleming
-
Patent number: 8968700Abstract: Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes employ an acyloxymethyl ketone reactive group, one or more amino acids for determining specificity, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY7 (diarylyrhodamine) quencher and a BODIPY (bora-diaza-indecene) dye.Type: GrantFiled: August 10, 2006Date of Patent: March 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Galia Blum, Georges von Degenfeld
-
Publication number: 20150056138Abstract: The invention features compounds and methods relating to hydroxy-proline analog inhibitors of the ASCT1 and ASCT2 neutral amino acid transporters useful for diagnostic purposes. These analogs are potent and selective inhibitors of ASCT2 and ASCT1-mediated amino acid transport as evidenced by significantly reduced glutamine or alanine transport-associated currents or radiolabeled substrate (amino acid) uptake in Xenopus oocytes expressing ASCT2 or ASCT1. Selectivity has been established in the same manner whereby reduced substrate associated current or substrate uptake is unobserved in Xenopus oocytes expressing ATA2, SN1, or EAAT(s) (excitatory amino acid transporter). The compounds and methods of the invention include radiolabeled inhibitors that can be used in research or clinical applications (e.g., for the treatment of cancer or ischemia-related central nervous system injury).Type: ApplicationFiled: October 15, 2014Publication date: February 26, 2015Inventor: Stephanie Lynn Martinelli
-
Patent number: 8961927Abstract: The invention provides MRI detectable species of formula (I) Dp-Sn-Nm??(I) wherein D is a MRI detectable moiety S is a spacer N is a molecule of a nutrient or pseudo-nutrient n is 0 or an integer m is an integer and p is an integer. These compounds are useful for internalizing into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalized in normal healthy cells thus allowing the diagnosis of tumors. The internalization of the MRI detectable moiety involves the nutrients or pseudo-nutrients transporting system. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion.Type: GrantFiled: July 2, 2010Date of Patent: February 24, 2015Assignee: Bracco Imaging S.p.A.Inventors: Silvio Aime, Valentina Mainero, Simonetta Chirich Geninatti, Claudia Cabella
-
Patent number: 8961949Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).Type: GrantFiled: June 26, 2009Date of Patent: February 24, 2015Assignee: Japan Science and Technology AgencyInventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
-
Patent number: 8961924Abstract: A method for synthesizing a complex having the formula: [L3MO3]? wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from ?2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or b) reaction of pertechnetate or perrhenate with a Lewis acid and L3, wherein the synthesis (a) or (b) is carried out in an aqueous medium.Type: GrantFiled: March 10, 2009Date of Patent: February 24, 2015Assignee: University of ZurichInventors: Roger Alberto, Henrik Braband
-
Patent number: 8956589Abstract: Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid ? peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid ? peptide aggregate.Type: GrantFiled: February 26, 2010Date of Patent: February 17, 2015Assignee: Shiga University of Medical ScienceInventors: Ikuo Tooyama, Hiroyasu Taguchi, Shigehiro Morikawa, Makoto Urushitani, Daijiro Yanagisawa, Tomone Nagae, Nobuaki Shirai, Koichi Hirao, Masanari Kato, Hirohiko Kimura, Takashi Okada
-
Patent number: 8957215Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: GrantFiled: April 23, 2012Date of Patent: February 17, 2015Assignee: Navidea Biopharmaceuticals, Inc.Inventors: Ylva Gravenfors, Catrin Jonasson, Jonas Malmstrom, Gunnar Nordvall, David Pyring, Can Slivo, Daniel Sohn, Peter Strom, David Wensbo
-
Patent number: 8951503Abstract: The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vitro and/or in vivo in aqueous media. The range of detection is between about 400 and 800 nm. In particular, a sensory devise is implemented in a mammal to determine sugar levels. Specifically, a dye is combined with a conjugated nitrogen-containing heterocyclic aromatic boronic acid-substituted bis-onium compound in the presence of a sugar, such as fructose or glucose. The viologens are preferred as the aromatic conjugated nitrogen-containing boronic acid substituted compounds. The method is useful to determine sugar levels in a human being.Type: GrantFiled: August 8, 2008Date of Patent: February 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Bakthan Singaram, Ritchie A. Wessling
-
Publication number: 20150037253Abstract: The present invention relates to copper, gallium and technetium coordinated thiosemicarbazone-pyridylhydrazine (substituted at the pyridine ring with a substituted benzothiazole or stilbene moiety) complexes and methods thereof. Such compounds possess utility in PET imaging and diagnosis of amyloid diseases.Type: ApplicationFiled: December 6, 2012Publication date: February 5, 2015Inventors: Paul Donnelly, James Hickey, Kevin Barnham, Sin Chun Lim
-
Publication number: 20150037252Abstract: The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a solid tumor in a localised manner via the co-administration of particulate material and a cellular toxin. The method of the present invention is useful in a range of therapeutic treatments including the treatment of primary and metastatic tumors.Type: ApplicationFiled: April 20, 2012Publication date: February 5, 2015Applicant: THE UNIVERSITY OF SYDNEYInventors: Brian Stanley Hawkett, Trevor William Hambley, Nicole Sarah Bryce, Thi Thuy Binh Pham, Nirmesh Jain
-
Publication number: 20150031988Abstract: The present invention provides a therapeutic system that is widely applicable to general solid cancers, can achieve both a reduction in side effects of cancer therapy and suppression of cancer recurrence and metastasis, and requires no expensive drug such as an antibody; and a nanoparticle for internal radiation therapy. A system for internal radiation therapy of a vascular lesion site comprising: a device comprising a means for acquiring image data showing a position of a vascular lesion site, and a means for positioning a needle, which should be punctured into the vascular lesion site, at the vascular lesion site based on the image data; and a nanoparticle comprising an amphiphilic block polymer comprising a hydrophilic block having a sarcosine unit and a hydrophobic block having a lactic acid unit, and a substance labeled with a ?-ray emitting nuclide. The nanoparticle for internal radiation therapy.Type: ApplicationFiled: September 12, 2012Publication date: January 29, 2015Inventors: Eri Takeuchi, Isao Hara, Ryo Yamahara, Eiichi Ozeki, Shunsaku Kimura, Kensuke Kurihara
-
Patent number: 8940274Abstract: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are functionalised BTMs useful in the method, as well as methods of preparing such functionalised BTMs under mild conditions.Type: GrantFiled: November 23, 2011Date of Patent: January 27, 2015Assignee: GE Healthcare LimitedInventors: Michelle Avory, Harry John Wadsworth, Robert James Domett Nairne
-
Patent number: 8940273Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.Type: GrantFiled: January 15, 2013Date of Patent: January 27, 2015Assignee: Mallinckrodt LLCInventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
-
Publication number: 20150023873Abstract: The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.Type: ApplicationFiled: October 31, 2012Publication date: January 22, 2015Applicants: Lantheus Medical Imaging, Inc., Yale UniversityInventors: Albert J. Sinusas, Joseph G. Akar, Richard R. Cesati, Heike S. Radeke, Stephen B. Haber
-
Patent number: 8936777Abstract: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.Type: GrantFiled: February 8, 2011Date of Patent: January 20, 2015Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Edward H. Cheesman, Joel Lazewatsky, Heike S. Radeke, Enrico Mongeau, Dianne D. Zdankiewicz, Marybeth Devine
-
Publication number: 20150017097Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.Type: ApplicationFiled: October 2, 2014Publication date: January 15, 2015Applicant: BRACCO DIAGNOSTICS INC.Inventors: Edmund C. METCALFE, Jo Anna MONTEFERRANTE, Margaret NEWBORN, Irene KUCHAREWICZ ROPIAK, Ernst SCHRAMM, Gregory W. WHITE, Julius P. ZODDA
-
Patent number: 8932558Abstract: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.Type: GrantFiled: September 29, 2008Date of Patent: January 13, 2015Assignee: Plaxgen IncInventor: Shanmugavel Madasamy
-
Patent number: 8932557Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.Type: GrantFiled: May 22, 2012Date of Patent: January 13, 2015Assignee: Eli Lilly and CompanyInventors: Gang Chen, Umesh B. Gangadharmath, Dhanalakshmi Kasi, Anjana Sinha, Wei Zhang, Kai Chen, Vani P. Mocharla
-
Publication number: 20150010472Abstract: Methods for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests by administration of a pharmaceutical composition comprising adenosine and dipyridamole are described. The methods allow for the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, where the dosages of each of these compounds are below their respective dosages when the compounds are used as a single agent. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented, are compositions, unit dosage forms, and kits that are useful in performing the methods.Type: ApplicationFiled: January 29, 2013Publication date: January 8, 2015Applicant: Adenobio N.V.Inventor: Philippe Gorny
-
Patent number: 8926944Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.Type: GrantFiled: August 3, 2012Date of Patent: January 6, 2015Assignee: Molecular Insight PharmaceuticalsInventors: John W. Babich, Craig Zimmerman, John L. Joyal, Genliang Lu
-
Patent number: 8926945Abstract: The invention concerns compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium. The invention also concerns methods for obtaining said compounds, screening methods capable of selecting such compounds for chemical synthesis thereof and their diagnostic applications, in particular in PET, PET/IRM, PET CT imaging.Type: GrantFiled: October 9, 2006Date of Patent: January 6, 2015Assignee: GuerbetInventors: Marc Port, Claire Corot, Thierry Gautheret
-
Publication number: 20150004097Abstract: The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.Type: ApplicationFiled: September 18, 2014Publication date: January 1, 2015Inventors: Thomas E. Rogers, John N. Freskos
-
Patent number: 8920777Abstract: The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer.Type: GrantFiled: August 15, 2011Date of Patent: December 30, 2014Assignee: IGF Oncology, LLCInventor: Hugh McTavish
-
Publication number: 20140377175Abstract: Provided herein are compositions and methods of preparing nanoparticle aggregates.Type: ApplicationFiled: June 24, 2014Publication date: December 25, 2014Inventors: Jacob Berlin, Desiree van Haute
-
Publication number: 20140377176Abstract: The present invention is related to silicon nanoparticles, a pharmaceutical composition comprising silicon nanoparticles, a method for synthesis of the silicon nanoparticles and their use for in vivo diagnostics, visualization of drug delivery or staining of cells, biological processes or pathways. The silicon nanoparticles are characterised that they comprise a silicon core of a size of 1 to 10 nm and are terminated with allylamine or poly(allylamine) comprising up to 10 allylamine groups.Type: ApplicationFiled: December 12, 2012Publication date: December 25, 2014Inventors: Holger Stephan, Ralf Bergmann, Alexander Ruffani, Luisa DeCola
-
Patent number: 8916137Abstract: The present invention provides symmetric carbocyanine dyes and dye precursors useful for fluorescence microscopy, and methods of making and using same.Type: GrantFiled: November 9, 2009Date of Patent: December 23, 2014Assignee: The General Hospital CorporationInventors: Scott A. Hilderbrand, Ralph Weissleder, Fangwei Shao
-
Patent number: 8911706Abstract: The present invention is about bifunctional chelating agents (BCA) conjugated mannosyl human serum albumin (MSA) and its radioisotope labeled compounds for imaging immune system such as macrophages, Kupffer cells, reticuloendothelial system (RES), and lymphatic system. The present invention comprises BCA-MSA conjugates, their radiolabeled compounds, and kits for radiolabeing. The present invention improved radiolabeling procedure, showed higher lymphatic system uptake, and enabled image by positron emission tomography (PET).Type: GrantFiled: January 27, 2010Date of Patent: December 16, 2014Assignee: SNU R&DB FoundationInventors: Jae Min Jeong, Myung Chul Lee, June Key Chung, Dong Soo Lee
-
Patent number: 8911707Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.Type: GrantFiled: February 27, 2013Date of Patent: December 16, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: William E. Klunk, Chester A. Mathis, Jr., Yanming Wang
-
Publication number: 20140363374Abstract: Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition.Type: ApplicationFiled: August 12, 2014Publication date: December 11, 2014Inventor: Lawrence R. Bernstein
-
Publication number: 20140356283Abstract: Embodiments of the present disclosure provide for water soluble polyethylene glycol (PEG)-polymeric melanin (PEG-melanin) nanoparticles, methods of using the PEG-melanin nanoparticle, methods of making the PEG-melanin nanoparticle, methods of imaging a diseases or condition (e.g., pre-cancerous tissue, cancer, or a tumor), and the like. Embodiments of the present disclosure can be used in multimodal imaging (e.g., photoacoustic, nuclear, magnetic, fluorescent, and the like).Type: ApplicationFiled: May 28, 2014Publication date: December 4, 2014Inventors: Zhen Cheng, Quli Fan, Kai Cheng, Xiang Hu
-
Publication number: 20140348746Abstract: The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.Type: ApplicationFiled: March 17, 2014Publication date: November 27, 2014Applicant: VisEn Medical, Inc.Inventor: Narasimhachari Narayanan